SCHEMBL1704740

SCHEMBL1704740

O=c1nc[nH]c2ncncc12

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RPS6KA5 O75582 1/20 0.37
SMN1; SMN2 Q16637 2/20 0.36
LMNA P02545 1/20 0.36
TSHR P16473 1/20 0.36
ADORA2A P29274 1/20 0.36
SLC6A4 P31645 1/20 0.36
ADRA1A P35348 1/20 0.36
XDH P47989 1/20 0.36
RAB9A P51151 1/20 0.36
BLM P54132 1/20 0.36
KDM4A O75164 1/20 0.34
KDM4B O94953 1/20 0.34
KDM5C P41229 1/20 0.34
KDM4C Q9H3R0 1/20 0.34
KDM5B Q9UGL1 1/20 0.34
KDM3A Q9Y4C1 1/20 0.34
ALDH1A1 P00352 3/20 0.32
KDM4E B2RXH2 1/20 0.32
TP53 P04637 1/20 0.32
HPGD P15428 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27923088 0.74 KDM4E (0.40) RPS6KA5LMNAALDH1A1KDM4EHPGD
SCHEMBL10131569 0.71 DYRK1A (0.46) SMN1; SMN2LMNATSHRADORA2ASLC6A4
SCHEMBL2226029 0.71 ADORA2A (0.44) RPS6KA5ADORA2A
SCHEMBL29381263 0.71 ADORA2A (0.44) RPS6KA5ADORA2A
Purine SCHEMBL3157 0.70
Purine SCHEMBL29456595 0.70
Purine SCHEMBL2120547 0.70 KDM4A (0.38) RPS6KA5SMN1; SMN2LMNAXDHBLM
Purine SCHEMBL6421376 0.70 KDM4A (0.38) RPS6KA5SMN1; SMN2LMNAXDHBLM
SCHEMBL1085884 0.69 AXL (0.55) RPS6KA5PIM1FLT3AURKAAURKB
Purine SCHEMBL37119 0.68 KDM4A (0.37) RPS6KA5SMN1; SMN2BLMKDM4AKDM4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0733633-A1 Heterocyclic compounds, their production and use TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1996-09-25 EP claimed
EP-2960341-B1 NOVEL TISSUE PROTECTIVE ERYTHROPOIETIN RECEPTOR (NEPOR) AND METHODS OF USE MOLECULAR HEALTH GMBH (DE) 2018-06-27 EP disclosed
EP-3263717-A1 NOVEL TISSUE PROTECTIVE ERYTHROPOIETIN RECEPTOR (NEPOR) AND METHODS OF USE Molecular Health GmbH (DE) 2018-01-03 EP disclosed
US-20170315128-A1 NOVEL TISSUE PROTECTIVE ERYTHROPOIETIN RECEPTOR (NEPOR) AND METHODS OF USE MOLECULAR HEALTH GMBH (DE) 2017-11-02 US disclosed
EP-2435581-B1 METHODS OF USE OF A NOVEL TISSUE PROTECTIVE ERYTHROPOIETIN RECEPTOR (NEPOR) MOLECULAR HEALTH GMBH (DE) 2017-07-26 EP disclosed
EP-2960341-A1 NOVEL TISSUE PROTECTIVE ERYTHROPOIETIN RECEPTOR (NEPOR) AND METHODS OF USE Molecular Health GmbH (DE) 2015-12-30 EP disclosed
EP-2492355-B1 Tissue protective erythropoietin receptor (nepor) and methods of use MOLECULAR HEALTH GMBH (DE) 2015-04-08 EP disclosed
US-20140296318-A1 NOVEL TISSUE PROTECTIVE ERYTHROPOIETIN RECEPTOR (NEPOR) AND METHODS OF USE MOLECULAR HEALTH GMBH (DE) 2014-10-02 US disclosed
US-8357501-B2 Tissue protective erythropoietin receptor (NEPOR) and methods of use MOLECULAR HEALTH GMBH (DE) 2013-01-22 US disclosed
EP-2109690-B9 EPH-B4 SPECIFIC SIRNA FOR REDUCING EPO-INDUCED TUMOR CELL GROWTH DURING ANEMIA TREATMENT IN CANCER PATIENTS, TISSUE PROTECTIVE ERYTHROPOIETIN RECEPTOR (NEPOR) AND METHODS OF USE. MOLECULAR HEALTH GMBH (DE) 2012-10-24 EP disclosed
US-20090306186-A1 NOVEL TISSUE PROTECTIVE ERYTHROPOIETIN RECEPTOR (NEPOR) AND METHODS OF USE ALEPOR GMBH & CO. KG 2009-12-10 US disclosed
EP-2109690-A1 NOVEL TISSUE PROTECTIVE ERYTHROPOIETIN RECEPTOR (NEPOR) AND METHODS OF USE Alepor GMBH & CO. KG (DE) 2009-10-21 EP disclosed
WO-2009068677-A1 NOVEL TISSUE PROTECTIVE ERYTHROPOIETIN RECEPTOR (NEPOR) AND METHODS OF USE ALEPOR GMBH & CO. KG (DE) 2009-06-04 WO disclosed
US-20060128735-A1 Substituted thiophenes with antibacterial activity REPLIDYNE, INC. (US) 2006-06-15 US disclosed
US-7030137-B2 Substituted thiophenes with antibacterial activity REPLIDYNE, INC. (US) 2006-04-18 US disclosed
EP-1603881-A2 SUBSTITUTED THIOPHENES WITH ANTIBACTERIAL ACTIVITY Replidyne, Inc. (US) 2005-12-14 EP disclosed
US-20050009833-A1 Substituted thiophenes with antibacterial activity REPLIDYNE, INC. 2005-01-13 US disclosed
WO-2004078119-A2 SUBSTITUTED THIOPHENES WITH ANTIBACTERIAL ACTIVITY REPLIDYNE INC. (US) 2004-09-16 WO disclosed
EP-0733633-B1 Heterocyclic compounds, their production and use TAKEDA CHEMICAL INDUSTRIES LTD (JP) 2003-05-28 EP disclosed
EP-0733633-A1 Heterocyclic compounds, their production and use TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1996-09-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009833-A1 Substituted thiophenes with antibacterial activity TST, MTR, NSUN3 RPS6KA5 490/4885SMN1; SMN2 1124/4885LMNA 4467/4885
US-20060128735-A1 Substituted thiophenes with antibacterial activity TST, MTR, NSUN3 RPS6KA5 490/4885SMN1; SMN2 1124/4885LMNA 4467/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.